Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1990-06-28
1992-02-25
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
552610, A61K 3156, C07J 5300
Patent
active
050913808
ABSTRACT:
N-monosubstituted adamantyl
orbornanyl 17.beta.-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5.alpha.-reductase inhibitors of the formula: ##STR1## wherein R is a hydrocarbon radical selected from substituted or unsubstituted 1- or 2-adamantyl or 1-, 2- or 7-norbornanyl and pharmaceutically acceptable salts or esters thereof. Also described is a pharmaceutical formulation. The above compounds are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of acne, seborrhea, female hirsutism, and systemically in treatment of benign prostatic hypertrophy.
REFERENCES:
patent: 2227876 (1941-01-01), Bolt
patent: 3239417 (1966-03-01), Tullin et al.
patent: 3264301 (1966-08-01), Doorenbos et al.
patent: 3285918 (1966-11-01), Doorenbos et al.
patent: 4220775 (1980-09-01), Rasmusson et al.
patent: 4317817 (1982-03-01), Blohm et al.
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4732897 (1988-03-01), Caineli et al.
patent: 4760071 (1988-01-01), Rasmusson et al.
patent: 4845104 (1989-07-01), Carlin et al.
patent: 4859681 (1989-08-01), Rasmusson et al.
patent: 4882319 (1989-11-01), Holt et al.
patent: 4910226 (1990-03-01), Holt et al.
Endo., vol. 91, No. 2 (1972) by Neri et al.
Steroids, 14, 269 (1969), by Nayfeh et al.
Endo., vol. 92, p. 1216 (1973) by Voigt and Hsia.
J. Pharm. Sci., 62, 4, pp. 638-640 (1973) by Doorenbos and Solomons.
J. Pharm. Sci., 60, 8, pp. 1234-1235 (1971), by Doorenbos and Brown.
J. Pharm., 63, 4, pp. 620-622 (1974) by Doorenbos and Kim.
J. Med. Chem. (1986) 29 (11): pp. 2298-3115 by Rasmusson et al.
Prostate (1986) 9 (1): pp. 65-75 by Brooks et al.
Steroids (1986) 47 (1).degree., pp. 1-19 by Brooks et al.
Endocr. (1985) 117 (2): pp. 571-579, by Liang et al.
J. Med. Chem. (1984) 27 (12).degree., pp. 1690-1701, by Rasmusson et al.
J. Org. Chem. (1981) vol. 46, No. 7, pp. 1442-1446.
Chem. Abstracts, vol. 95, 109055j, by T. Liang et al.
JNCI, vol. 74, No. 2, pp. 475-481 (Feb. 1985).
The Prostate, vol. 10, pp. 189-197 (1987) by G. L. Andriole et al.
J. Endocr., vol. 57, pp. 111-121 (1973), by K. D. Bingham et al.
Toxicol. Appl. Pharmacol., vol. 103, pp. 222-227 (1990), by G. L. Kedderis et al.
Bioinorganic Chemistry, 17, pp. 372-376 (1986) by B. W. Metcalf et al.
Biochemistry, 1990, vol. 29, pp. 2815-2824, by M. A. Levy et al.
J. Med. Chem., 1990, vol. 33, pp. 943-950, D. A. Holt et al.
J. Steroid Biochem., vol. 34, Nos. 1-6, pp. 571-575 (1989), by M. A. Levy et al.
J. Med. Chem., vol. 33, pp. 937-942 (1990) by D. A. Holt et al.
TIPS, Dec. 1989, vol. 10, pp. 491-495, by D. W. Metcalf et al.
Steroids, vol. 35, No. 3 (Mar. 1980), pp. 1-7.
Prostate, vol. 9, pp. 311-318 (1986) by N. Stone et al.
Steroids, vol. 47, No. 1, pp. 1-19 (1986) by J. R. Brooks et al.
Lancet, Nov. 1986, No. 8515, pp. 1095-1096.
J. Clin. Endocrin. and Metab., vol. 55, No. 1, pp. 188-193 (1987).
Patel Gool F.
Rasmusson Gary H.
Tolman Richard L.
Caruso Charles M.
Merck & Co. , Inc.
Mitri Salvatore C.
Shah Mukund J.
Venkat Jyothsna
LandOfFree
N-monosubstituted adamantyl/norbornanyl 17.beta.-carbamides of 3 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-monosubstituted adamantyl/norbornanyl 17.beta.-carbamides of 3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-monosubstituted adamantyl/norbornanyl 17.beta.-carbamides of 3 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1893065